Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027599 · ClinicalTrials.gov registry record · Phase 2
APC8015 and Bevacizumab in Treating Patients With Prostate Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00027599: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00027599 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00027599, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of APC8015 combined with bevacizumab in treating patients who have undergone radiation therapy and/or surgery and who have progressive prostate cancer. Biological therapies such as APC8015 use different ways to stimulate the immune system and stop cancer cells from growing. Monoclonal antibodies such as bevacizumab can locate tumor cells and kill them without harming normal cells. Combining monoclonal antibody therapy with biological therapy may kill more cancer cells.
Interventions
- BIOLOGICAL bevacizumab
- BIOLOGICAL sipuleucel-T
- PROCEDURE in vitro-treated peripheral blood stem cell transplantation
- BIOLOGICAL therapeutic autologous dendritic cells
- BIOLOGICAL prostatic acid phosphatase-sargramostim fusion protein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2001-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00027599
The ClinicalTrials.gov registry entry for NCT00027599 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which bevacizumab is the first listed.
NCT00027599 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00027599 about?
NCT00027599 is a clinical study titled "APC8015 and Bevacizumab in Treating Patients With Prostate Cancer". Phase II trial to study the effectiveness of APC8015 combined with bevacizumab in treating patients who have undergone radiation therapy and/or surgery and who have progressive prostate cancer. Biological therapies such as APC8015 use different ways to stimulate the immune system and stop cancer cel...
What is the current status of trial NCT00027599?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2001-12.
What interventions are being tested in trial NCT00027599?
The interventions under investigation include: bevacizumab (BIOLOGICAL), sipuleucel-T (BIOLOGICAL), in vitro-treated peripheral blood stem cell transplantation (PROCEDURE), therapeutic autologous dendritic cells (BIOLOGICAL), prostatic acid phosphatase-sargramostim fusion protein (BIOLOGICAL).
Who is sponsoring clinical trial NCT00027599?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.